Press Release / February 10th, 2023 Vancouver, BC – Cube Psytech Holdings Inc. (the “Company” or “CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce that it has entered into a letter of intent (“LOI”) to acquire Translational Life Sciences (“TLS”). TLS will join Cube Psytech Corp. and Cube Wellness Products Inc. under the umbrella of the Cube group of companies. Under the LOI, CUBE will issue approximately 50% of its outstanding shares, warrants and options to shareholders, directors and employees of TLS in exchange for 100% of the outstanding share capital of TLS resulting in TLS acquiring one third of the share capital in CUBE. The acquisition is conditional on CUBE completing a private placement or other financing of a minimum of $2 million. CUBE believes that the acquisition of TLS will greatly strengthen CUBE’s position in the areas of psychedelic research and development. TLS is a science first company comprised of a top-notch team of scientists and technologists with R&D labs at the University of British Columbia. Highlights of TLS work in their whole drug discovery pipeline include: Successful profiling of over 1,000 extracted botanical compounds 2.5 years of brain receptor profiling data on over 200 species of mushrooms in cell culture and animals. Health Canada approved Dealer License that allows commercial scalability of production and product development in various psilocybin-based drugs. Proprietary efficacy and consistency testing protocols that insure natural functional and psychedelic products result in clinical grade standards suitable for global market. TLS’ primary focus has been, and will continue to be, the creation of intellectual property and patented psychedelic drug therapies used to help patients manage a variety of mental health issues in addition to concussions, eating disorders, obesity, and diabetes. “As a company our mission is to create products that help people and in TLS we have found a great partner in this mission. TLS is developing technologies that will help us create and bring to market important products that truly make a difference. With this strengthened combined team we will continue to lead the field in terms of science and business development and take a huge step forward as a company” states CUBE Co-Founder and CEO, Erick Factor “TLS is excited to be joining forces with Cube Psytech. Our common mission is to translate psychedelic science from the bench to the bedside. We look forward to joining their talented team to bring best-in-class naturally derived therapeutics to market” states TLS President and Founder, Dr. William Panenka, The Company also announces that is has initiated a private placement to issue up to 16,000,000 unit for gross proceeds of $4,000,000 at a price of $0.25 per unit. Each unit is comprised of one common share of the Company and one-half warrant. Each full warrant will have an exercise price of $0.40 per share and will expire three years after issue date. Proceeds from the private placement will be used for working capital purposes to fund operations, continue development on its property in Ontario, and to pursue a listing on a public exchange. On Behalf of The Board of Directors Erick Factor Chief Executive Officer

Cube Psytech Corp. founder and COO will be proudly presenting the scientific evidence of microdosing its clinical background at Psychedelics Medicine Tour 2022, Dallas, TX, USA.